>>**Entry Name: Batimastat,** BAN, INN, USAN

Synonym(s): N^4-Hydroxy-N^1-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide, 9CI. [4-(*N*-Hydroxyamino)-2-isobutyl-3-(thiophen-2-ylthiomethyl)succinyl]phenylalanine *N*-methylamide. Barinatrix. BB-94



CAS Registry Number: 130370-60-4

Molecular Formula: $C_{23}H_{31}N_3O_4S_2$
Molecular Weight: 477.648
Accurate Mass: 477.175597
Percentage Composition: C 57.84%; H 6.54%; N 8.80%; O 13.40%; S 13.43%
Use/Importance: Matrix metalloproteinase inhibitor. Restricts tumour growth
Physical Description: Cryst. (MeOH aq.)
Melting Point: Mp 236-238°
Calculated Log P Data: Log P 3.09 (calc)
Other Data: Stereochem. is (2*R*,3*S*,1'*S*)

>>**Derivative:** Na salt

CAS Registry Number: 130464-84-5
Physical Description: Solid
Melting Point: Mp 170°
Optical Rotation: $[\alpha]_D$ –67 (c, 1 in MeOH)

References:

Pat. Coop. Treaty (WIPO), 1990, *British Biotech*, 90 05 719; *CA*, **113**, 212677c, *(synth, pharmacol)*
Davies, B. *et al.*, *Cancer Res.*, 1993, **53**, 2087, *(pharmacol)*
Wang, X. *et al.*, *Cancer Res.*, 1994, **54**, 4726, *(pharmacol)*
Chirivi, R.G.S. *et al.*, *Int. J. Cancer*, 1994, **58**, 460, *(pharmacol)*
Taraboletti, G. *et al.*, *J. Natl. Cancer Inst.*, 1995, **87**, 293, *(pharmacol)*